A new Scientific Statement released today by the Endocrine Society highlights research gaps associated with the negative effects of opioid use on the endocrine system.
Sanofi and Regeneron’s Dupixent scores second win in Phase III COPD trial
Share this article Dupixent is an interleukin-4 receptor alpha antagonist monoclonal antibody. Image Credit: Net Vector / Shutterstock. Sanofi and Regeneron have reported positive interim